These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 23843149)

  • 1. Kinase in motion: insights into the dynamic nature of p38α by high-pressure NMR spectroscopic studies.
    Nielsen G; Jonker HR; Vajpai N; Grzesiek S; Schwalbe H
    Chembiochem; 2013 Sep; 14(14):1799-806. PubMed ID: 23843149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into MAPK p38alpha DFG flip mechanism by accelerated molecular dynamics.
    Filomia F; De Rienzo F; Menziani MC
    Bioorg Med Chem; 2010 Sep; 18(18):6805-12. PubMed ID: 20724167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMR spectroscopic investigations of the activated p38α mitogen-activated protein kinase.
    Nielsen G; Schwalbe H
    Chembiochem; 2011 Nov; 12(17):2599-607. PubMed ID: 22012687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.
    Bukhtiyarova M; Karpusas M; Northrop K; Namboodiri HV; Springman EB
    Biochemistry; 2007 May; 46(19):5687-96. PubMed ID: 17441692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The third conformation of p38α MAP kinase observed in phosphorylated p38α and in solution.
    Akella R; Min X; Wu Q; Gardner KH; Goldsmith EJ
    Structure; 2010 Dec; 18(12):1571-8. PubMed ID: 21134636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human p38α mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod.
    Suplatov D; Kopylov K; Sharapova Y; Švedas V
    J Biomol Struct Dyn; 2019 May; 37(8):2049-2060. PubMed ID: 29749295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorophore labeled kinase detects ligands that bind within the MAPK insert of p38α kinase.
    Getlik M; Simard JR; Termathe M; Grütter C; Rabiller M; van Otterlo WA; Rauh D
    PLoS One; 2012; 7(7):e39713. PubMed ID: 22768308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved expression, purification, and crystallization of p38alpha MAP kinase.
    Bukhtiyarova M; Northrop K; Chai X; Casper D; Karpusas M; Springman E
    Protein Expr Purif; 2004 Sep; 37(1):154-61. PubMed ID: 15294293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A screening system for the identification of refolding conditions for a model protein kinase, p38alpha.
    Cowan RH; Davies RA; Pinheiro TT
    Anal Biochem; 2008 May; 376(1):25-38. PubMed ID: 18294951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors.
    Astolfi A; Iraci N; Manfroni G; Barreca ML; Cecchetti V
    ChemMedChem; 2015 Jun; 10(6):957-69. PubMed ID: 26012502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Structural Overview of p38α Mitogen-Activated Protein Kinase in Complex with ATP-Site and Non-ATP-Site Binders.
    Astolfi A; Manfroni G; Cecchetti V; Barreca ML
    ChemMedChem; 2018 Jan; 13(1):7-14. PubMed ID: 29210532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrogen-exchange mass spectrometry reveals activation-induced changes in the conformational mobility of p38alpha MAP kinase.
    Sours KM; Kwok SC; Rachidi T; Lee T; Ring A; Hoofnagle AN; Resing KA; Ahn NG
    J Mol Biol; 2008 Jun; 379(5):1075-93. PubMed ID: 18501927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening.
    Astolfi A; Iraci N; Sabatini S; Barreca ML; Cecchetti V
    Molecules; 2015 Aug; 20(9):15842-61. PubMed ID: 26334265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modeling of p38α mitogen-activated protein kinase inhibitors through 3D-QSAR and molecular dynamics simulations.
    Chang HW; Chung FS; Yang CN
    J Chem Inf Model; 2013 Jul; 53(7):1775-86. PubMed ID: 23808966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics in the p38alpha MAP kinase-SB203580 complex observed by liquid-state NMR spectroscopy.
    Honndorf VS; Coudevylle N; Laufer S; Becker S; Griesinger C
    Angew Chem Int Ed Engl; 2008; 47(19):3548-51. PubMed ID: 18389508
    [No Abstract]   [Full Text] [Related]  

  • 16. Lipid molecules induce p38α activation via a novel molecular switch.
    Tzarum N; Eisenberg-Domovich Y; Gills JJ; Dennis PA; Livnah O
    J Mol Biol; 2012 Dec; 424(5):339-53. PubMed ID: 23079240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and characterization of a substrate selective p38alpha inhibitor.
    Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
    Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMR Spectroscopy to Study MAP Kinase Binding to MAP Kinase Phosphatases.
    Peti W; Page R
    Methods Mol Biol; 2016; 1447():181-96. PubMed ID: 27514807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the binding affinity of p38α MAP kinase inhibitors by partial least squares regression.
    Basant N; Durante C; Cocchi M; Menziani MC
    Chem Biol Drug Des; 2012 Sep; 80(3):455-70. PubMed ID: 22642504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis of p38α regulation by hematopoietic tyrosine phosphatase.
    Francis DM; Różycki B; Koveal D; Hummer G; Page R; Peti W
    Nat Chem Biol; 2011 Nov; 7(12):916-24. PubMed ID: 22057126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.